Literature DB >> 20110858

Bone marrow transplantation temporarily improves pancreatic function in streptozotocin-induced diabetes: potential involvement of very small embryonic-like cells.

Yiming Huang1, Magda Kucia, Lala-Rukh Hussain, Yujie Wen, Hong Xu, Jun Yan, Mariusz Z Ratajczak, Suzanne T Ildstad.   

Abstract

BACKGROUND: The role of bone marrow (BM)-derived cells in pancreatic beta-cell regeneration remains unresolved. We examined whether BM-derived cells are recruited to the site of moderate pancreatic injury and contribute to beta-cell regeneration.
METHODS: Low-dose streptozotocin (STZ) treatment was used to induce moderate pancreatic damage and hyperglycemia. Enhanced green fluorescent protein-positive (EGFP) BM chimeras were evaluated for beta-cell regeneration after STZ treatment.
RESULTS: To test the hypothesis that pancreatic tissue injury induces a stromal cell-derived factor (SDF)-1 gradient to chemoattract the stem cells, we evaluated the expression of mRNA for SDF-1 in damaged pancreatic tissue. SDF-1 was significantly increased in the pancreas after damage, peaking at day 10. The majority of BM cells expressing mRNA for pancreatic development markers were detected in the subpopulation of CD45/Sca-1/Lin very small embryonic-like (VSEL) cells. VSEL cells mobilized from BM to peripheral blood in response to pancreatic damage, peaking in peripheral blood at day 5, and were enriched in the pancreas 10 to 15 days after STZ treatment. To confirm a role for BM-derived cells in pancreatic beta-cell regeneration, we prepared EGFP-->B6 chimeras. In the EGFP chimeras, EGFP cells were detected around duct and islets and were positive for insulin after STZ treatment. However, STZ-induced hyperglycemia was reduced only transiently (49-77 days) after pancreatic injury.
CONCLUSIONS: These data suggest that VSEL cells are mobilized into injured pancreatic tissue and contribute to beta-cell regeneration. Transplantation of BM-derived cells improves the function of injured pancreas, although the response is not sufficient to restore sustained normoglycemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20110858      PMCID: PMC2844483          DOI: 10.1097/TP.0b013e3181c9dc7d

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  52 in total

1.  Patterns of hemopoietic reconstitution in nonobese diabetic mice: dichotomy of allogeneic resistance versus competitive advantage of disease-resistant marrow.

Authors:  C L Kaufman; H Li; S T Ildstad
Journal:  J Immunol       Date:  1997-03-01       Impact factor: 5.422

2.  Reversal of experimental diabetes by multiple bone marrow transplantation.

Authors:  Meenal Banerjee; Anil Kumar; Ramesh R Bhonde
Journal:  Biochem Biophys Res Commun       Date:  2005-03-04       Impact factor: 3.575

3.  Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction.

Authors:  Magda Kucia; Buddhadeb Dawn; Greg Hunt; Yiru Guo; Marcin Wysoczynski; Marcin Majka; Janina Ratajczak; Francine Rezzoug; Suzanne T Ildstad; Roberto Bolli; Mariusz Z Ratajczak
Journal:  Circ Res       Date:  2004-11-18       Impact factor: 17.367

4.  Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient.

Authors:  Marcin Wysoczynski; Ryan Reca; Janina Ratajczak; Magda Kucia; Neeta Shirvaikar; Marek Honczarenko; Michael Mills; Jens Wanzeck; Anna Janowska-Wieczorek; Mariusz Z Ratajczak
Journal:  Blood       Date:  2004-08-24       Impact factor: 22.113

5.  Hematologic effects of flt3 ligand in vivo in mice.

Authors:  K Brasel; H J McKenna; P J Morrissey; K Charrier; A E Morris; C C Lee; D E Williams; S D Lyman
Journal:  Blood       Date:  1996-09-15       Impact factor: 22.113

6.  Insulin-promoter-factor 1 is required for pancreas development in mice.

Authors:  J Jonsson; L Carlsson; T Edlund; H Edlund
Journal:  Nature       Date:  1994-10-13       Impact factor: 49.962

7.  Effect of FLT3 ligand and granulocyte colony-stimulating factor on expansion and mobilization of facilitating cells and hematopoietic stem cells in mice: kinetics and repopulating potential.

Authors:  M Neipp; T Zorina; M A Domenick; B G Exner; S T Ildstad
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

8.  Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice.

Authors:  H Li; C L Kaufman; S S Boggs; P C Johnson; K D Patrene; S T Ildstad
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

9.  Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor.

Authors:  R Haas; A D Ho; U Bredthauer; S Cayeux; G Egerer; W Knauf; W Hunstein
Journal:  Exp Hematol       Date:  1990-02       Impact factor: 3.084

10.  Bone marrow transplantation as a strategy for treatment of non-insulin-dependent diabetes mellitus in KK-Ay mice.

Authors:  S Than; H Ishida; M Inaba; Y Fukuba; Y Seino; M Adachi; H Imura; S Ikehara
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

View more
  21 in total

1.  Nutritional programming of pancreatic β-cell plasticity.

Authors:  David J Hill
Journal:  World J Diabetes       Date:  2011-08-15

2.  Direct comparison of the abilities of bone marrow mesenchymal versus hematopoietic stem cells to reverse hyperglycemia in diabetic NOD.SCID mice.

Authors:  Edith J Arany; Muhammad Waseem; Brenda J Strutt; Astrid Chamson-Reig; Adam Bernardo; Elizabeth Eng; David J Hill
Journal:  Islets       Date:  2018-08-15       Impact factor: 2.694

3.  Human very small embryonic-like cells generate skeletal structures, in vivo.

Authors:  Aaron M Havens; Yusuke Shiozawa; Younghun Jung; Hongli Sun; Jincheng Wang; Samantha McGee; Anjali Mishra; L Susan Taichman; Theodora Danciu; Yajuan Jiang; Gregory Yavanian; Elizabeth Leary; Paul H Krebsbach; Denis Rodgerson; Russell S Taichman
Journal:  Stem Cells Dev       Date:  2012-09-28       Impact factor: 3.272

4.  Role of bone marrow-derived mesenchymal stem cells in a rat model of severe acute pancreatitis.

Authors:  Xiao-Huang Tu; Jing-Xiang Song; Xiao-Jun Xue; Xian-Wei Guo; Yun-Xia Ma; Zhi-Yao Chen; Zhong-Dong Zou; Lie Wang
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

5.  Combinatorial treatment of bone marrow stem cells and stromal cell-derived factor 1 improves glycemia and insulin production in diabetic mice.

Authors:  H Cheng; Y C Zhang; S Wolfe; V Valencia; K Qian; L Shen; Y L Tang; W H Hsu; M A Atkinson; M I Phillips
Journal:  Mol Cell Endocrinol       Date:  2011-07-27       Impact factor: 4.102

Review 6.  Stem cell-based strategies for the treatment of type 1 diabetes mellitus.

Authors:  Yujie Wen; Bo Chen; Suzanne T Ildstad
Journal:  Expert Opin Biol Ther       Date:  2010-11-29       Impact factor: 4.388

7.  Detection, characterization, and spontaneous differentiation in vitro of very small embryonic-like putative stem cells in adult mammalian ovary.

Authors:  Seema Parte; Deepa Bhartiya; Jyoti Telang; Vinita Daithankar; Vinita Salvi; Kusum Zaveri; Indira Hinduja
Journal:  Stem Cells Dev       Date:  2011-03-23       Impact factor: 3.272

Review 8.  The great migration of bone marrow-derived stem cells toward the ischemic brain: therapeutic implications for stroke and other neurological disorders.

Authors:  Cesar V Borlongan; Loren E Glover; Naoki Tajiri; Yuji Kaneko; Thomas B Freeman
Journal:  Prog Neurobiol       Date:  2011-08-30       Impact factor: 11.685

Review 9.  Stem cell-based therapeutic applications in retinal degenerative diseases.

Authors:  Yiming Huang; Volker Enzmann; Suzanne T Ildstad
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

10.  PDX1-engineered embryonic stem cell-derived insulin producing cells regulate hyperglycemia in diabetic mice.

Authors:  Sudhanshu P Raikwar; Nicholas Zavazava
Journal:  Transplant Res       Date:  2012-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.